Introduction: high mortality among individuals receiving retreatment for tuberculosis (RT-TB) persists, although reasons for these poor outcomes
TB, where drug susceptibility testing (DST) was unavailable or delayed [3, 4] . With increased global access to second line drugs and DST, the WHO guideline for RT-TB has moved to drug-susceptibility based regimens [4, 5] . However, DST coverage amongst bacteriologically-confirmed pulmonary RT-TB patients is less than 40% in the African region [1] . In addition, up to 65% of RT-TB patients present as smear negative, extrapulmonary or as patients without laboratory testing [6] and thus are not included in calculations of DST coverage. In this study, we assess RT-TB outcomes, rates of bacteriologic confirmation of RT-TB and factors associated with mortality in RT-TB. (Table 4) .
Methods
Overall RT-TB treatment success was 56.4%, with mortality during treatment of 19.4% (Table 1) . Thirteen percent of RT-TB patients were being treated for at least the third TB episode (Table 1 ). During our study window, 84% of RT-TB patients were initially started on the category II regimen. As detailed in (Table 3) . Of those with phenotypic DST testing, 18%
were resistant to 3 or more of the 4 first line drugs tested. Sixty two percent of resistant isolates were found to have resistance to first line drugs other than rifampin, which would have been missed had they been tested with Xpert alone (resistance to ethambutol, isoniazid and/or streptomycin) ( Table 3) .
Discussion
In our cohort of RT-TB patients from a Ghanaian academic referral clinic, 19.4% of patients died during retreatment, higher than the 4-13% mortality rate of published RT-TB cohorts worldwide [8] [9] [10] [11] [12] [13] [14] [15] [16] .
Persons returning after LTFU, living with HIV, and without DST results were at increased mortality risk.
Our findings underscore the critical-and urgent-importance of global recommendations for all RT-TB presumptive patients to have access to DST. Though availability of the empiric category II regimen during our study [4] We found that when mortality occurred, it was early in RT-TB therapy.
While one study in Tanzanian RT-TB patients found 6.5% mortality in the first two months [13] , we observed over 10% mortality within the first fifteen days of therapy. This high early mortality rate likely reflects late advanced disease presentations. Similarly, delayed return to care
and resulting advanced disease may also explain our finding of increased mortality in those presenting after LTFU (aHR=8.27).
Cohorts from India and Uganda have also shown higher mortality amongst RT-TB patients returning after LTFU [12, 14] . Attempts for early recognition of LTFU and innovated methods for rapid reengagement in care may also be critical to lower RT-TB mortality rates.
Others have previously shown that patients with RT-TB have higher rates of drug resistance, with MDR amongst RT-TB cases estimated to be five times higher than amongst new TB cases [7, 8, 22] .
Importantly, we observed additional drug-resistance patterns, including 40% isoniazid-resistance amongst tested isolates. Isoniazid resistance is associated with poor clinical outcomes [23] with recent guidelines issued for global roll out of an isoniazid-resistant regimen [5] . In our cohort, 62% of drug-resistant isolates were resistant to drugs other than rifampin ( Finally, KBTH is a referral center, possibly limiting the generalizability of our findings to RT-TB patients in similar settings.
Conclusion
Years of empiric treatment for RT-TB in low and middle resource settings, such as the application of category II regimens or blind reapplication of category I, has led to inadequate treatment with resultant poor success rates, drug resistance, morbidity and mortality.
With the END TB strategy's emphasis on patient centered care and human rights [24] , universal access to comprehensive first-line genotypic and phenotypic DST with individualized regimens in RT-TB is not a luxury, but an urgent imperative.
What is known about this topic
• To curb the global tuberculosis epidemic, we must target key groups at high-risk of drug resistance and poor treatment outcomes;
• Retreatment tuberculosis patients have both higher mortality and drug-resistance rates when compared tuberculosis patients treated for the first time;
• The reasons for high mortality among retreatment tuberculosis patients are unclear.
What this study adds
• High rates of extrapulmonary tuberculosis and smear/culture negative disease among retreatment tuberculosis patients in Ghana highlight the barriers to achieving individualized regimens and the need for improved diagnostics;
• More than half of drug-resistant isolates were resistant to drugs other than rifampin, suggesting access to comprehensive first-line drug susceptibility testing, rather than reliance on Xpert testing alone, is critical in this population;
• Early recognition of tuberculosis treatment loss to follow up, and innovated methods for rapid re-engagement in care may lower retreatment tuberculosis mortality rates.
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